Access cutting-edge lymphoma treatment through this clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.
Access lymphoma specialists in Chicago at no cost
This study follows strict safety protocols and ethical guidelines
All study-related lymphoma treatment provided free
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients with advanced solid tumors and lymphomas.
Sponsor: Novartis Pharmaceuticals
Check if you qualify for this lymphoma clinical trial in Chicago, IL
If you're searching for lymphoma treatment options in Chicago, IL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.